The granting of this patent is expected to provide protection in the US as well as in major markets internationally.
Russell Mitchell, CEO of PuraMed Bioscience, said: “The filing of our initial patent is the first of many steps in our efforts to build a strong intellectual property portfolio. A strong IP portfolio will provide us with the necessary protection as we introduce our products to the marketplace as well as increasing long-term shareholder value.”